Search company, investor...

HiPharma

hi-pharma.com

Founded Year

2017

Stage

Merger | Merged

About HiPharma

HiPharma is focused on the development of medical cannabis products that meet the growth and production standards of the Medical Unit of the Ministry of Health.

Headquarters Location

Israel

Missing: HiPharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: HiPharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing HiPharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

HiPharma is included in 1 Expert Collection, including Cannabis.

C

Cannabis

3,834 items

These companies participate in - or service businesses that participate in - the legal cannabis industry. Our definition of cannabis includes both marijuana and hemp (and all derivatives). The collection includes both "plant-touching" and "non-plant-touching" businesses.

HiPharma Frequently Asked Questions (FAQ)

  • When was HiPharma founded?

    HiPharma was founded in 2017.

  • What is HiPharma's latest funding round?

    HiPharma's latest funding round is Merger.

  • Who are the investors of HiPharma?

    Investors of HiPharma include Medivie Therapeutic.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.